Evidence map›Paper›PMID 33979989›Full record

ArticleHaematologica2021

Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the

Marius Bill, Chinmayee Goda, Felice Pepe, Hatice Gulcin Ozer, Betina McNeil, Xiaoli Zhang, Malith Karunasiri, Rohan Kulkarni, Sonu Kalyan, Dimitrios Papaioannou and 6 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. PROTACs: The Future of Leukemia Therapeutics.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Marius BillThe Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden.
Chinmayee GodaThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Felice PepeThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Hatice Gulcin OzerThe Ohio State University, Department of Biomedical Informatics, Columbus, OH.
Betina McNeilThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Xiaoli ZhangThe Ohio State University, Department of Biomedical Informatics, Columbus, OH.
Malith KarunasiriThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Rohan KulkarniThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Sonu KalyanThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Dimitrios PapaioannouThe Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Gregory FerenchakThe Ohio State University, Comprehensive Cancer Center, Columbus, OH.
Ramiro GarzonThe Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
James E BradnerDana-Faber Cancer Institute, Boston, MA.
Guido MarcucciCity of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010.
Michael A CaligiuriCity of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010.
Adrienne M DorranceThe Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH. adrienne.dorrance@osumc.edu.
The Ohio State University · USCity of Hope · USDana-Farber Cancer Institute · USUniversity Hospital Carl Gustav Carus · DE

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteNuclear ProteinsBromodomain Containing ProteinsCell Cycle ProteinsGene DuplicationHumansMyeloid-Lymphoid Leukemia ProteinTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsMyeloid-Lymphoid Leukemia ProteinNuclear ProteinsTranscription Factors

Identifiers

PMID33979989
PMCPMC8409020
OpenAlexW3160191900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.